

Special Issue

Therapeutics Agents for Neural Repair 2023

Message from the Guest Editor

An insult to the central nervous system (CNS) usually leads to permanent and irreversible pathological conditions. Events such as stroke, trauma, or neurodegenerative diseases have a strong impact on the physiological, psychological, and social behaviors of patients. For these reasons, it is urgent to develop therapeutic strategies that can specifically target these problems. This Special Issue is dedicated to “Therapeutic Agents for Neural Repair”, and it is mainly focused on the use of pharmaceutical agents administrated alone or in combination with other therapeutic approaches. The proposed topics include, but are not limited to, the following:

- Pathologies of the CNS (Parkinson's, Alzheimer's, Huntington's, multiple sclerosis, depression, autism, Machado–Joseph, amyotrophic lateral sclerosis, stroke, traumatic brain injury, and spinal cord injury).
- Therapeutic approaches (molecular therapy, cell therapy, gene therapy, deep brain/epidural stimulation, and tissue engineering).
- Personalized medicine.
- Biomarkers of disease.
- In vitro/ex vivo studies.
- In vivo preclinical studies.
- Clinical studies.

Guest Editor

Dr. Nuno Silva

Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Campus de Gualtar, 4710-057 Braga, Portugal

Deadline for manuscript submissions

closed (31 December 2023)



Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/158002

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)





Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us. We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)